Four Key Genes are Biomarkers Associated with Immunity in Neuroglioma

Abstract Background: Glioma is the most common intracranial tumor, with glioblastoma being the most malignant. However, its treatment is very few, and targeted therapy is an important breakthrough in treatment. Methods: Numerous genes are differentially expressed during the progression of glioma, some of which may play a key role. To find key genes, we analyzed three multi-sample microarrays (GSE4290, GSE54004, and GSE29796) in the GEO database to obtain intersection differential genes among them. We entered all DEGs into the STRING database and characterized the protein interactions of these DEGs as visual PPI networks by Cytoscape software. Also, we used the GEPIA2 and CGGAdatabase to predict the relationship between key genes and the prognosis of glioma patients.Results: A total of 222 up-regulated genes and 127 down-regulated genes were identified. Four genes(FN1, LAMB1, FAM20C, and COL6A1) were significantly negatively correlated with malignant glioma survival. Expression levels of four genes increased with the glioma grade. All gene expression is more common in IDH wild glioma and are enriched in the Mesenchymal subtype(AUC>0.8). In addition,they can be defined as hazard factors for glioma. We found that these genes were co-expressed and jointly involved in the infiltration of immune cells in tumors. Conclusion: In conclusion, FN1, LAMB1, FAM20C, and COL6A1 is associated with poor prognosis in glioma patients. These genes might be clinical targets of glioma immunotherapy.